From Berlin to Valencia: Looking Ahead to 2026
The momentum built in Berlin does not end here. Targeting Phage Therapy 2025 confirmed that the field has reached a turning point, where clinical reality, regulatory structure, and industrial engagement are beginning to align.
Building on this foundation, Targeting Phage Therapy 2026 in Valencia, Spain, will focus on the next essential step: making phage therapy operational, accessible, and scalable. Read More
Program & Key Dates of 2026
Phage Therapy Is Entering a New Era.
Science, Regulation, Innovation, and Clinical Deployment United in Valencia
Targeting Phage 2026 will bring together leading international experts to discuss how phage therapy is transitioning from experimental approaches toward clinically deployable solutions.
Confirmed Speakers for 2026
Turning Evolution into Therapy: A New Strategy to Fight Antibiotic-Resistant Infections
Benjamin K. Chan, Yale University, USA
The Human Virome in Chronic Infection: What Patient Phages Teach Us About Therapeutic Phage Design
Katrine Whiteson, UC Irvine, USA
Personalized Bacteriophage Therapy in Germany and Beyond – A Consensus-Based Guideline
Annika Y. Classen, Cologne University Hospital, Germany
The Qualified Presumption of Safety (QPS) Qualification of Lytic Bacteriophages: Scientific Criteria and Regulatory Perspectives
Juan Evaristo Suárez, Universidad de Oviedo, Spain
Chronic Respiratory Infections in the Inflamed Lung: Host–Pathogen Interactions and Opportunities for Phage Therapeutics
Paula Zamora, University of Kansas Medical Center, USA
From Bioreactor to Patient: Scalable Manufacturing and Delivery of Therapeutic Phages
Danish J. Malik, Loughborough University, United Kingdom
Phage for Sustainable and Scalable Infection Control in Aquaculture
Adelaide Almeida, Universidade de Aveiro, Portugal
Advancing Phage Therapy for Chronic Infections: From Experimental Evidence to Clinical Use
Joana Azeredo, University of Minho, Portugal
Bacteriophages Redesigned: Engineering of Next-Generation Phage Therapeutics and Diagnostics
Martin J. Loessner, ETH Zürich, Switzerland
France launches its first public GMP platform to produce large batches of therapeutic phages at affordable scale
Frédéric Laurent, Hospices Civils de Lyon, France
Phage Therapy in Livestock Disease Models: Lessons for Animal and Human Health
Robert Atterbury, University of Nottingham, United Kingdom
Personalized Phage Therapy at the Hannover Medical School: barriers, challenges, and next steps
Evgenii Rubalskii, Medizinische Hochschule Hannover, Germany
Unraveling the Nasopharyngeal Phageome in Post-Weaning Piglets: Advances and Perspectives
Oscar Mencía-Ares, Universidad de León, Spain
Phage–Pseudomonas Interactions: Changes in Host Physiology and the Potential Impact on Phage Therapy
Piotr Golec, University of Warsaw, Poland
Short Oral Accepted
Phage–antibiotic synergy re-sensitizes MDR Klebsiella biofilms and suppresses resistance
Tinatini Tchatchiashvili, Jena University Hospital, Germany
Modular Platform for Efficient Phage Purification
Isabel Marie Nowak, Technische Hochschule Mittelhessen, Germany
Operationalizing Clinical Phage Therapy Within a National Regulatory Framework: The Eliava Model
Mariam Dadiani, Eliava Phage Therapy Center, Georgia
Genomic indicators of bacteriophage susceptibility in ESBL-producing uropathogenic E. coli
Debora Satie Nagano, Kyorin University, Japan
The EU legal framework for one-size-fits-all versus personalized phage therapy
Timo Faltus, Martin-Luther-University Halle-Wittenberg, Germany
Biohybrids Composed of PRF and GELs with Antibacterial Phages for Controlled Therapeutic Delivery in Infected Wounds
Farzaneh Moghtader, TiPhage, Turkey
Investigating Phage-Antibiotic Synergy Against Multidrug-Resistant Infections
Emma Kane, Yale University, USA
Intravenous versus intravenous and inhaled delivery of bacteriophages: Pharmacokinetics and pharmacodynamics in pigs with or without ventilator-associated pneumonia
Viviane Oliveira, CIBER, Spain
E. Coli Bacteriophages: A Natural Alternative for Managing Neonatal Diarrhea in Swine
Javier Quero, Exopol S.L., Spain
Inhibition of a Bacterial Antiviral System by Chemical Compounds
Dziugas Sabonis, Vilnius University, Lithuania
Adaptive Targeting: A High-Throughput Screening Strategy to Overcome Evolved Bacterial Resistance in Phage Therapy
Biswajit Biswas, US Navy, USA
Who is Attending Targeting Phage Therapy 2026
LXbio Pharmaceuticals, Portugal
Exopol S.L., Spain
Inteliphage, Belgium
Komplementäre Tiermedizin GmbH, Germany
MB Pharma, Czech Republic
Norm Hayvan Sağlık Hizm., Turkey
Phagos, France
Pharmabios Innova S.L., Spain
Phileo by Lesaffre, France
Syva, Spain
Vetoquinol SA, France
CEITEC Masaryk University, Czech Republic
Centro de Investigación Biomédica en Red, Spain
Comunius University Science Park, Slovakia
ETH Zürich, Switzerland
Tbilisi Medical Academy, Georgia
Hirszfeld’s Institute of Immunology and Experimental Therapy, Poland
Hospices Civils de Lyon, France
Hospital Universitario 12 de Octubre, Spain
Instituto Aragonés de Ciencias de la Salud, Spain
Jena University Hospital, Germany
Kyorin University, Japan
Loughborough University, United Kingdom
Martin-Luther-Universität Halle-Wittenberg, Germany
McMaster University, Canada
Medizinische Hochschule Hannover, Germany
Montpellier University, France
Naval Medical Research Command, USA
Nanyang Technological University, Singapore
Southwest University, China
Technische Hochschule Mittelhessen, Germany
UC Irvine, USA
Universidad de León, Spain
Universidad de Oviedo, Spain
Universidade de Aveiro, Portugal
University Hospital Duesseldorf, Germany
University Hospital Regensburg, Germany
University of Kansas Medical Center, USA
University of Milan, Italy
University of Minho, Portugal
University of Nottingham, United Kingdom
University of Verona, Italy
University of Warsaw, Poland
Victor Babeş University, Romania
Vilnius University Life Science Center, Lithuania
Vilnius University-EMBL PI, Lithuania
Yale University, USA
Updated till 11th May, 2026…
Call for Innovation & Awards
Phage Therapy 2026 invites researchers, clinicians, startups, and industry partners to present new solutions that move phage therapy forward in a concrete and operational way.
The objective is simple: Identify solutions that make phage therapy scientifically solid, clinically credible, and industrially deployable in the fight against antimicrobial resistance. Read More
Concluding Remarks : Targeting Phage Therapy 2025 did not close a chapter. It opened a new one
Targeting Phage Therapy 2025 marked a decisive moment for the field of phage therapy. What was once viewed mainly as an experimental or compassionate use approach has clearly entered a new phase, one defined by clinical structuring, regulatory engagement, and growing industrial readiness.
Over two days in Berlin, the conference brought together clinicians, researchers, regulators, and industry leaders from around the world. A clear and shared message emerged throughout the meeting: phage therapy is no longer just a scientific promise. Read More